medroxyprogesterone acetate

Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

medroxyprogesterone acetate

Apo-Medroxy (CA), Climanor (UK), Depo-Provera, Depo-SUBQ-Provera 104, Dom-Medroxyprogesterone (CA), Gen-Medroxy (CA), Novo-Medrone (CA), PMS-Medroxyprogesterone (CA), Provera, Ratio-MPA

Pharmacologic class: Hormone

Therapeutic class: Progestin

Pregnancy risk category X

FDA Box Warning

• Injection form may cause significant bone density loss. Loss increases with duration of use and may not be completely reversible. It is unknown if use during adolescence or early adulthood reduces peak bone mass and increases risk for osteoporotic fracture later in life.

• Injection form should be used as long-term contraceptive (more than 2 years) only if other contraceptive methods are inadequate.


Inhibits pituitary gonadotropin secretion, preventing follicular maturation, ovulation, and pregnancy


Suspension for depot injection: 150 mg/ml, 400 mg/ml

Suspension for depot subcutaneous injection: 104 mg/0.65 ml in prefilled single-use syringes

Tablets: 2.5 mg, 5 mg, 10 mg

Indications and dosages

Secondary amenorrhea

Adults: 5 to 10 mg/day P.O. for 5 to 10 days, starting at any time during menstrual cycle

Dysfunctional uterine bleeding; menses induction

Adults: 5 to 10 mg/day P.O. for 5 to 10 days, starting on day 16 or 21 of menstrual cycle

To prevent estrogen-related endometrial changes in postmenopausal women

Adults: 2.5 to 5 mg/day P.O. given with 0.625 mg conjugated estrogens P.O. (monophasic regimen); or 5 mg/day P.O. on days 15 to 28 of cycle, given with 0.625 mg conjugated estrogens P.O. daily throughout cycle (biphasic regimen)

Management of endometriosis-associated pain

Adults: 104 mg (Depot-subcutaneous-Provera) in anterior thigh or abdomen q 12 to 14 weeks

To prevent pregnancy

Adults: 150 mg (Depo-Provera) deep I.M. injection q 13 weeks or 104 mg (Depot-subcutaneous-Provera) in anterior thigh or abdomen q 12 to 14 weeks. Give first injection during first 5 days of normal menstrual period or first 5 postpartal days if patient isn't breastfeeding, or during sixth postpartal week if patient is breastfeeding exclusively.

Renal or endometrial cancer

Adults: 400 to 1,000 mg I.M.; may repeat weekly. If improvement occurs, decrease to 400 mg q month.

Off-label uses

• Advanced breast cancer


• Hypersensitivity to drug or its components

• Cerebrovascular or thromboembolic disease

• Hepatic dysfunction or disease

• Breast or genital cancer

• Undiagnosed vaginal bleeding

• Known or suspected pregnancy


Use cautiously in:

• seizure disorder, renal or cardiovascular disease, asthma, diabetes mellitus, depression, migraine

• history of hepatic disease.


• Before starting therapy, obtain thorough history and physical examination, with emphasis on breast and pelvic organs. Also obtain Pap smear, and repeat annually during therapy.

• With contraceptive use, rule out pregnancy before first dose and when more than 14 weeks have passed since previous dose.

• For I.M. injection, inject deep into gluteal, deltoid, or anterior thigh muscle. Rotate injection sites.

• Be aware that when drug is used to prevent estrogen-related endometrial changes in postmenopausal women, lowest dosage should be used for shortest time, because treatment exceeding 1 year correlates with cancer. (Some combination products have 0.3 mg estrogen/1.5 mg progesterone or 0.45 mg estrogen/1.5 mg progesterone.)

Adverse reactions

CNS: insomnia, migraine, nervousness, drowsiness, dizziness, fatigue, depression, mood changes

CV: thrombophlebitis, thromboembolism

EENT: diplopia, proptosis, retinal vascular lesions, papilledema

GI: abdominal pain, bloating

GU: amenorrhea, leukorrhea, spotting, cervical secretions, galactorrhea, breast tenderness and secretion, cervical erosions, pelvic pain, infertility

Hepatic: jaundice

Metabolic: fluid retention, hyperglycemia

Musculoskeletal: leg cramps, back pain

Respiratory: pulmonary embolism

Skin: pruritus, urticaria, rash, acne, alopecia, hirsutism, chloasma, melasma, sterile abscesses, induration at I.M. site

Other: weight and appetite changes, edema, angioedema, allergic reactions including anaphylaxis


Drug-drug. Bromocriptine: decreased bromocriptine efficacy

Carbamazepine, phenobarbital, phenytoin, rifampin: decreased contraceptive efficacy

Drug-diagnostic tests. Alkaline phosphatase, low-density lipoproteins: increased levels

High-density lipoproteins, pregnanediol excretion: decreased levels

Thyroid hormone assays: altered results

Drug-behaviors. Alcohol use: additive CNS depression

Patient monitoring

• Monitor patient for fluid retention and for signs and symptoms of thrombophlebitis, including pain, swelling, and redness of lower legs.

Assess for visual disturbances and headache. If ocular exam shows papilledema or retinal vascular lesions, drug should be discontinued.

• Evaluate liver function tests.

Watch for abdominal pain, fever, malaise, jaundice, darkened urine, and clay-colored stools.

Patient teaching

• Advise patient that drug may cause nausea, vomiting, headache, abdominal pain, painful breast swelling, and abnormal bleeding pattern. Instruct her to report these effects if pronounced.

Tell patient to promptly report bloating, swelling, appetite loss, rash, yellowed skin, mood changes or depression, nervousness, dizziness, chest pain, shortness of breath, visual disturbances, or severe headache.

• Teach patient how to perform breast self-exams.

• Tell patient she must undergo yearly physical examinations with Pap smear.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved

medroxyprogesterone acetate

A progestin, C24H34O4, used as an injectable contraceptive, in the treatment of amenorrhea and uterine bleeding, and, in combination with estrogen, in hormone replacement therapy.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

medroxyprogesterone acetate

A synthetic progestin, which is chemically similar to androgen. Medroxyprogesterone acetate is used primarily as a contraceptive; it is injected every three months, inhibiting gonadotropin secretion which, in turn, prevents follicular maturation and ovulation, and causes endometrial thinning.

Contraceptive, hormone replacement therapy, treatment of endometriosis, anti-androgenic for male sex offenders (causing chemical castration).
Adverse effects
Acne, dysmenorrhoea, birth defects if taken during pregnancy, headache, breast tenderness, increased facial hair, decreased scalp hair, insomnia, abdominal pain/discomfort, dizziness, asthenia (weakness or fatigue), and weight changes. It also carries an increased risk of coronary heart disease, breast cancer, stroke and pulmonary embolism.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

medroxyprogesterone acetate

Provera® Gynecology A contraceptive injected every 3 months, whichs inhibits gonadotropin secretion which, in turn, prevents follicular maturation and ovulation, and causes endometrial thinning Adverse effects Menstrual irregularities, weight changes, headache, nervousness, abdominal pain/discomfort, dizziness, asthenia–
weakness or fatigue. See Contraceptive.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in, the treatment of endometriosis associated pain.
After 6 months, the girls treated with medroxyprogesterone acetate had lost an average of 0.25% of their BMD, compared with their baseline level.
In contrast, most women in France who take norethindrone acetate or medroxyprogesterone acetate use oral estrogen.
The article states that depot medroxyprogesterone acetate (DMPA) "may suppress ovarian function and is classified as [World Health Organization] category 3." (Category 3 is reserved for conditions in which theoretical or proven risks usually outweigh the advantages of the contraceptive method.)
All the women received 0.625 mg Premarin for 30 days, and in the last 15 days of treatment were randomized to receive an additional 200 mg micronized progesterone or 10 mg medroxyprogesterone acetate. A neuropsychological examiner blinded to treatment performed psychological evaluations at the start and end of the 30 days.
After 36 months of treatment, reduced genital pain with sexual intercourse was reported by 43% of women who received estrogen plus 10 mg of medroxyprogesterone acetate for the first 12 days of the cycle, 46% of women who received estrogen plus 2.5 mg of medroxyprogesterone acetate daily, and 44% of those who received estrogen plus 200 mg of micronized progesterone for the first 12 days of the cycle.
According to CNN, chemical castration is defined by the legislation as "the receiving of medication, including, but not limited to, medroxyprogesterone acetate treatment or its chemical equivalent, that, among other things, reduces, inhibits, or blocks the production of testosterone, hormones, or other chemicals in a person's body." (ANI)
In the present study, the contraceptive agent subtypes used by pregnant women included medroxyprogesterone acetate 5 mg (n=9), estradiol valerate 2 mg+norgestrel 0.5 mg (n=4), ethinyl estradiol 0.03 mg+levonorgestrel 0.15 mg (n=4), ulipristal 30 mg (n=2), medroxyprogesterone acetate 150 mg/ml (n=2), ethinyl estradiol 0.02 mg+gestodene 0.075 mg (n=2), norethisterone enanthate 50 mg+estradiol valerate 5 mg (n=1), desogestrel 75 [micro]g (n=1), progesterone 50 mg/ml (n=1), dydrogesterone 10 mg (n=1), and norethindrone 5 mg (n=1), provided that one woman had used one or more types of agents.
launch of Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL single-dose vial, a generic version of the brand drag, Pfizer's Depo-Provera.
Mylan NV (NASDAQ: MYL), a global pharmaceutical company, announced yesterday that it has launched its Medroxyprogesterone Acetate Injectable (MPA) Suspension USP, 150mg/mL Single-Dose Vial, a generic version of the brand drug, Pfizer's Depo-Provera, in the United States.